[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563064":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":45,"collaborators":47,"id":59,"slug":20,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":20,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":83,"whyStopped":20,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Imperial College London","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DE-iPTV radiotherapy","EXPERIMENTAL","Patients will undergo a radiotherapy planning scan, and an upto date MRI brain with contrast. Patients will receive 5 fractions of DE-iPTV radiotherapy over 1 week.",[13],"Radiation: DE-iPTV",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","DE-iPTV","Dose-escalated VMAT-based radiotherapy, as previously described in our planning study",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Lillie Pakzad-Shahabi, BSc MSc","CONTACT","02033118427","beat-breast@imperial.ac.uk",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},"Matt Williams, FRCR PhD","matthew.williams@imperial.ac.uk",[31],{"facility":5,"status":20,"city":32,"state":20,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"London","SW7 2AZ","United Kingdom",{"type":36,"coordinates":37},"Point",[38,39],-0.12574,51.50853,{"lat":39,"lon":38},[42,44],{"name":43,"role":24,"phone":20,"phoneExt":20,"email":26},"Lillie Pakzad Shahabi, BSc MSc",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},{"type":46,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[48,50,52,55,57],{"name":49,"class":6},"University of Leicester",{"name":51,"class":6},"Centro Nacional de Investigaciones Oncologicas CARLOS III",{"name":53,"class":54},"East and North Hertfordshire NHS Trust","OTHER_GOV",{"name":56,"class":6},"Norfolk and Norwich University Hospitals NHS Foundation Trust",{"name":58,"class":6},"Imperial College Healthcare NHS Trust","100563064",false,"NCT06611306","BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.","BEAT-Breast - Improving Outcomes for Breast Cancer Patients With Brain Metastases: a Pilot Nonrandomised Single Arm Phase 2 Clinical Trial in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy","BEAT-Breast","Inclusion Criteria\n\n1. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up\n2. Adult (aged 16+) patients, resident in the United Kingdom.\n3. Histologically confirmed primary breast cancer with brain metastases on MRI imaging\n4. The treating oncologist considers whole-brain radiotherapy to be the most suitable treatment outside of the trial.\n5. Eastern Cooperative Oncology Group Performance status 0, 1 or 2\n6. Able to respond to question about their quality of life, symptoms, and side effects remotely (via telephone assessments\n7. Life expectancy from extra-cranial disease \\>3 months\n\nExclusion Criteria\n\n1. Leptomeningeal disease\n2. \"Miliary\" pattern of metastases: patients with over 15 metastases are excluded (clinician-based assessment)\n3. Cystic metastases\n4. Previous whole or partial brain radiotherapy (previous surgery or SRS is acceptable)\n5. Plan for hippocampal-sparing whole brain radiotherapy.\n6. Unable to give informed consent.\n7. Prognosis less than 3 months\n8. Pregnant or nursing women\n9. Unable to complete a brain MRI and\u002For known allergy to gadolinium.","ALL","16 Years","100 Years",{"count":70,"type":71},42,"ESTIMATED","INTERVENTIONAL",[74],"NA","The aim of this study is to demonstrate if it is possible to delivering a novel and modern radiotherapy approach (Dose Escalated internal PTV (DE-iPTV)) and to collect health related quality of life in patients whose breast cancer has spread to the brain (brain metastases) at 8 weeks post enrolling into the study.\n\nThe main questions that have been set out to to answer are:\n\n* Is it possible to deliver the novel radiotherapy approach, DE-iPTV?\n* Is it possible to measure health -related quality of life?\n* What impact does the novel radiotherapy approach have on: patient's quality of life, control of the brain metastasis (control of the lesion) and steroid use?\n\nParticipants will:\n\n* Receive 5 doses of radiotherapy\n* Complete weekly quality of life (EQ-5D) assessments and medication (steroid) diaries (via telephone\u002F postal) until 12 weeks post enrolment\n* Be reviewed in clinic with up-to-date MRI scans at 8, 12 and 24 weeks post-enrolment\n* Complete a more detailed HRQoL panel of assessments will be assessed at baseline, 8 weeks, 12 weeks and 24 weeks post enrolment.",[77,78],"Brain Metastases, Adult","Breast Cancer",[80,81,82],"Radiotherapy","Brain metastases","Metastatic Breast Cancer","NOT_YET_RECRUITING","2024-10-10",{"date":86,"type":87},"2024-10-15","ACTUAL",{"date":89,"type":71},"2025-01-06",{"date":91,"type":71},"2026-12",{"name":5,"class":6},1]